16 results about "Conjugated protein" patented technology

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

To provide methods and apparatus for simultaneously detecting a quantity and / or concentration within a large range of protein.SOLUTION: Some embodiments described herein relate to a method that includes separating an analyte-containing sample via electrophoresis in a capillary. The capillary is loaded with a chemiluminescence agent, such as luminol, that is configured to react with the analyte (e.g., HRP-conjugated proteins) to produce a signal indicative of a concentration and / or quantity of analyte at each location along the length of the capillary. A first image of the capillary containing the analytes and the chemiluminescence agent is captured over a first period of time. A second image of the capillary containing the analytes and the chemiluminescence agent is captured over a second, longer, period of time. A concentration and / or quantity of a first population of analytes at a first location is determined using the first image, and a concentration and / or quantity of a second population of analytes at a second location is determined using the second image.SELECTED DRAWING: None

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The invention belongs to the technical field of biology, and particularly relates to a Prussian blue nano test strip for detecting an African horse pestivirus antibody as well as a preparation method and application of the Prussian blue nano test strip. A sample pad, a combination pad, a chromatography detection membrane and a water absorption pad are sequentially fixed on the supporting bottom plate; the chromatography detection membrane is provided with a detection line and a quality control line, the detection line is coated with staphylococcus A protein, and the quality control line is coated with a monoclonal antibody of African horse pestivirus VP7 recombinant protein; and the combination pad is coated with an African horse pestivirus VP7 delta N1-129 recombinant protein fragment coupled with Prussian blue nanoparticles. According to the invention, Prussian blue nano is used as a coupling tracer, and the specific reaction of an antigen and an antibody is fully utilized to detect the African horse pestivirus antibody. After the conjugate is combined with a corresponding antibody, a result can be clearly observed, and the conjugate is good in stability, high in sensitivity and strong in specificity, has a clinical application function and huge development potential, and is an extremely ideal antibody test strip detection material.

A major obstacle in the field of biotherapeutics is the need for platform technologies that enable high bioavailability and long-term therapeutic exposure of biotherapies in localized disease. Traditional approaches result in problematic trade-offs, such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST), which can bind to biological structures, such as the extracellular matrix, via heparan sulfate without the undesired neutralizing effects on the activity of activin A, myostatin, and GDF11, as full-length follistatin does. The present invention relates to fusion or conjugated proteins, compositions thereof, constructs or vectors encoding them, their medical uses, and methods for biotherapeutics.

This invention discloses a bifunctional compound containing a targeting moiety for a conjugated protein kinase, membrane-bound tyrosine / threonine 1 (PKMYT1), a pharmaceutical composition thereof, and a method for treating PKMYT1-related disorders or diseases, such as cancer.

1. Name of the product for this design: Bucket (Baojian Compound Protein Powder Solid Beverage). 2. Purpose of this design: For packaging health food products. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key features: the front view.

This invention provides libraries of Botulinum neurotoxin A (BoNT / A) protease variants for stepwise evolution of the enzyme to generate BoNT / A variants that can specifically cleave a desired cleavage site in a target protein. Related methods for performing stepwise evolution of BoNT / A with the BoNT / A variant libraries and simultaneous stepwise evolution of a desired substrate sequence in a target protein are also provided by the disclosure. Additionally provided in the disclosure are specifically evolved BoNT / A variant enzymes and conjugate proteins that specifically degrade intrinsically disordered proteins (IDPs) that are involved in human deceases, e.g., a-Synuclein. Polynucleotide sequences encoding the engineered BoNT / A proteases, expression vectors and related pharmaceutical compositions are also provided in this disclosure. Further encompassed by the invention are therapeutic methods that utilize the engineered BoNT / A enzymes in the treatment of various synucleinopathies.

Disclosed herein are high-throughput synthetic methods for deliberately and prospectively discovering molecular glues that can be used to form complex protein-ligand surfaces that facilitate interfacial binding to other proteins on a dispersed surface. Specifically, the present application discloses a high-throughput method that uses sulfur(VI) fluoride exchange (SuFEx) transformation and N-hydroxysuccinimide (NHS)-ester derivatized amide coupling to prospectively repurpose known ligands of a protein of interest as degraders and compounds capable of inducing proximity to other proteins. Disclosed herein are methods of developing known ligands of a target protein into degraders of the target protein. Also disclosed are methods of developing a novel small molecule chromatin-competitive inhibitor of the 11-19 Leukemia (ENL) YEATS domain into an effective degrader of ENL.

The present disclosure provides a system and method for detecting and quantifying two or more different antigen-binding proteins in a sample, which includes donor beads, acceptor beads, and conjugated proteins that can be incubated with the sample and the antigen-binding proteins quantified by a proximity-based homogeneous assay.

The present invention relates to a method for the production of haploid, polyhaploid and / or doubled haploid embryos, calli, seeds and / or plants of the species Helianthus annuus from isolated microspore cultures, more specifically to a method comprising contacting the isolated microspores with a histone deacetylase inhibitor (HDACi) and a complex protein composition. The present invention also provides a kit for producing a haploid, polyhaploid and / or doubled haploid embryo, callus, seed and / or plant of the species Helianthus annuus from at least one isolated microspore as well as the use of a histone deacetylase inhibitor (HDACi) and a complex protein composition for producing a haploid, polyhaploid and / or doubled haploid embryo, callus, seed and / or plant of the species Helianthus annuus. Finally, the present invention also relates to a population of haploid, polyhaploid and / or doubled haploid Helianthus annuus plants directly derived from at least one sunflower apical or lateral capitula.

1. Name of the designed product: package box (Baojian compound protein powder solid beverage). 2. Use of the designed product: for packaging health food. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The present disclosure relates to compositions and methods for altering, for example, enhancing the expression of FXN in vitro and / or in vivo, including but not limited to the development of engineered promoters. Such compositions include delivery by administration of adeno-associated virus (AAV) particles. The compositions and methods of the present disclosure are used to treat subjects diagnosed with or suspected of having Friedreich's Ataxia or another neuromuscular or neurological condition caused by a deficiency in the amount and / or function of FXN or associated with decreased expression or protein levels of FXN.

A purpose of the present invention is to provide a recombinant expression technique for producing a protein glutaminase in which decreases in thermostability are suppressed. A complex protein glutaminase according to the present invention is a thrombin cleavage product of a mutant propolypeptide comprising a propolypeptide sequence which includes a pro-sequence and a mature sequence of protein glutaminase, wherein a thrombin recognition sequence is introduced into a C-terminal region of the pro-sequence. The complex protein glutaminase includes: (A) a pro-sequence peptide having an N-terminal cleavage fragment of the thrombin recognition sequence at the C-terminal thereof; and (B) a mature protein glutaminase having a C-terminal cleavage fragment of the thrombin recognition sequence at an N-terminal thereof. Said complex protein glutaminase has an improved thermal denaturation temperature compared to non-complex protein glutaminases.

Disclosed is a) a conjugated peptide being conjugated with at least one reducing sugar and a degree of conjugation of at least 10 percent, preferably being in solid form such as powders; b) a method for preparing non-bitter conjugated protein hydrolysates comprising hydrolyzing a protein by at least one enzyme, mixing the resulting protein hydrolysate and at least one reducing sugar, heating the mixture to perform a Maillard reaction and drying the composition; c) a method for masking the bitter taste of a peptide comprising mixing a peptide and a reducing sugar, heating the mixture to perform a Maillard reaction and drying to obtain a powder; and d) the use of a conjugated peptide for food products, dietary supplements, pharmaceutical products and animal feed products.

The invention discloses preparation and weeding application of a composite protein-based nano quinclorac material, and belongs to the technical field of pesticide weeding. The method comprises the following steps: forming a compound protein solution by adopting isolated soybean protein and isolated whey protein in a specific proportion, adding quinclorac into the compound protein solution, fully mixing, and regulating the pH value of the system to 6.0-8.0; centrifuging, collecting supernate, and performing freeze drying to obtain the target composite protein-based nano quinclorac material. Experimental results show that the material shows excellent drug loading capacity, and the bioavailability of quinclorac is remarkably improved. In the weeding application, the material not only can efficiently remove weeds and reduce the herbicide application amount, but also enhances the safety to non-target organisms; meanwhile, the fertilizer has the functions of promoting the activity of effective microbial communities in soil and relieving pesticide stress, so that the soil health is effectively protected.